Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway

International Journal of Oncology

Volumn 39, Issue 4, 2011, Pages 1001-1009

  Wen, Gengyun ^a   Hong, Mei ^a,b   Li, Bingyan ^a,c   Liao, Wupeng ^a   Cheng, Simon K ^a   Hu, Burong ^a   Calaf, Gloria M ^a,d   Lu, Ping ^a   Partridge, Michael A ^a   Tong, Jian ^c   Hei, Tom K ^a,c,e  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

^d UNIVERSIDAD DE TARAPACÁ   (Chile)

^e Mailman School of Public Health   (United States)

Author keywords

Adhesion mediated signaling; Extracellular matrix; Metastasis; Mouse model; TGFBI

Indexed keywords

ASBESTOS; BETA ACTIN; CELL PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; S6 KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INDUCED PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BRONCHUS MUCOSA; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN H28; CELL STRAIN MET 5A; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; INVASIVE CARCINOMA; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS;

ASBESTOS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE; CELL LINE, TUMOR; CYCLIN D1; DISEASE PROGRESSION; DNA-BINDING PROTEINS; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR MATRIX PROTEINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MESOTHELIOMA; MUTATION; NEOPLASMS, MESOTHELIAL; ONCOGENE PROTEINS V-MOS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 79960882626     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1097     Document Type: Article

References (42)

1. Jaurand MC and Fleury-Feith J: Pathogenesis of malignant pleural mesothelioma. Respirology 10: 2-8, 2005.
2. Schins R and Hei TK: Genotoxic effects of particles. In: Particle Toxicology. Donaldson K and Borm P (eds.) CRC Press, London, pp287-300, 2006.
3. Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD and Purchio AF: cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol 11: 511-522, 1992.
4. Livshits L, Pampukha VM, Tereshchenko FA and Drozhyna GI: Gene symbol: TGFBI. Disease: Corneal dystrophy, lattice type. Hum Genet 124: 296-297, 2008.
5. Thapa N, Lee BH and Kim IS: TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta. Int J Biochem Cell Biol 39: 2183-2194, 2007. (Pubitemid 47484277)
6. Zhao YL, Piao CQ and Hei TK: Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 21: 7471-7477, 2002. (Pubitemid 35305574)
7. Harvey RD and Lonial S: PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol 3: 639-647, 2007.
8. Vasudevan KM and Garraway LA: AKT signaling in physiology and disease. Curr Top Microbiol Immunol 347: 105-133, 2010.
9. Wickenden JA and Watson CJ: Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. Breast Cancer Res 12: 202, 2010.
10. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ and Bussink J: The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4: 761-767, 2009.
11. Madhunapantula SV and Robertson GP: The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 22: 400-419, 2009.
12. Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH and Ge Y: RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 114: 2744-2752, 2009.
13. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005. (Pubitemid 40262113)
14. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
15. Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127-150, 2009.
16. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB and Testa JR: Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24: 6080-6089, 2005. (Pubitemid 43080058)
17. Pespeni MH, Hodnett M, Abayasiriwardana KS, Roux J, Howard M, Broaddus VC and Pittet JF: Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phospho-inositide-dependent kinase 1/Akt pathway. Cancer Res 67: 2865-2871, 2007. (Pubitemid 46548977)
18. Kane AB: Animal models of malignant mesothelioma. Inhalation Toxicol 18: 1001-1004, 2006.
19. Cole GW Jr, Alleva AM, Zuo JT, Sehgal SS, Yeow WS, Schrump DS and Nguyen DM: Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res 26: 809-821, 2006.
20. Sarbassov DD, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603, 2005. (Pubitemid 41540408)
21. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006. (Pubitemid 43199434)
22. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE and Pagano M: S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314: 467-471, 2006. (Pubitemid 44628968)
23. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007. (Pubitemid 47001784)
24. Billings PC, Whitbeck JC, Adams CS, Abrams WR, Cohen AJ, Engelsberg BN, Howard PS and Rosenbloom J: The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J Biol Chem 277: 28003-28009, 2002. (Pubitemid 34966750)
25. Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134, 2010.
26. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A and Villa E: Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34: 279-287, 2001. (Pubitemid 33010804)
27. Zervos MD, Bizekis C and Pass HI: Malignant mesothelioma 2008. Curr Opin Pulm Med 14: 303-309, 2008. (Pubitemid 351786540)
28. Robinson BW, Musk AW and Lake RA: Malignant mesothelioma. Lancet 366: 397-408, 2005. (Pubitemid 41073959)
29. Anderson HA, Lilis R, Daum SM, Fischbein AS and Selikoff IJ: Household-contact asbestos neoplastic risk. Ann NY Acad Sci 271: 311-323, 1976.
30. Risberg B, Nickels J and Wågermark J: Familial clustering of malignant mesothelioma. Cancer 45: 2422-2427, 1980. (Pubitemid 10109135)
31. Whysner J, Covello VT, Kuschner M, Rifkind AB, Rozman KK, Trichopoulos D and Williams GM: Asbestos in the air of public buildings: a public health risk? Prev Med 23: 119-125, 1994. (Pubitemid 24125924)
32. Yang H, Testa JR and Carbone M: Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 9: 147-157, 2008.
33. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E and Dirix LY: Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80: 892-897, 1999. (Pubitemid 29209856)
34. Nam JO, Jeong HW, Lee BH, Park RW and Kim IS: Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin. Cancer Res 65: 4153-4161, 2005.
35. Zhao YL, Piao CQ and Hei TK: Overexpression of Betaig-h3 gene downregulates integrin alpha5beta1 and suppresses tumorigenicity in radiation-induced tumorigenic human bronchial epithelial cells. Br J Cancer 86: 1923-1928, 2002.
36. Zhao Y, El-Gabry M and Hei TK: Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol Carcinog 45: 84-92, 2006. (Pubitemid 43202581)
37. Wen G, Calaf GM, Partridge MA, Echiburú-Chau C, Zhao Y, Huang S, Chai Y, Li B, Hu B and Hei TK: Neoplastic transformation of human small airway epithelial cells induced by arsenic. Mol Med 14: 2-10, 2008. (Pubitemid 351356880)
38. Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001. (Pubitemid 32467043)
39. Chiarugi P and Giannoni E: Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 76: 1352-1364, 2008.
40. Zhang Y, Wen G, Shao G, Wang C, Lin C, Fang H, Balajee AS, Bhagat G, Hei TK and Zhao Y: TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res 69: 37-44, 2009.
41. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ and Wang XF: Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 22: 308-321, 2008. (Pubitemid 351214273)
42. Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C and Oehler MK: Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer 128: 1570-1584, 2011.